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Abstract
Background: Clean intermittent self-catheterisation is an important management option for people who cannot
empty their bladder effectively. Recurrent urinary tract infections are common in these patients. Data from recent
studies suggest that antibiotic prophylaxis may be beneficial in reducing infection risk, but the effectiveness of this
intervention remains uncertain.
Methods/design: This is a 52-site, patient randomised superiority trial set in routine care comparing an
experimental strategy of once daily antibiotic prophylaxis for 12 months against a control strategy of no
prophylaxis in people who carry out self-catheterisation and suffer recurrent urinary tract infections. The
primary outcome is number of urinary tract infections during a 12-month treatment period. Both groups
will otherwise receive usual care including on demand treatment courses of antibiotics for urinary tract
infection. Participants and their clinicians will not be blinded to the allocated intervention, but central trial
staff managing and analysing trial data will, as far as possible, be unaware of participant allocation. The
analysis will follow intention-to-treat principles.
Discussion: This trial was commissioned and funded by the United Kingdom National Health Service
following prioritisation of the research question by the National Institute for Health and Care Excellence.
Trial registration: ISRCTN67145101 EUDRACT2013-002556-32. Registered on 25 October 2013.
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Background
Clean intermittent self-catheterisation (CISC) is a fre-
quently used intervention for people who cannot empty
their bladder effectively due to bladder outlet obstruc-
tion or failure of bladder muscle contraction which may
be associated with neurological disease [1]. Patients
needing CISC are taught how to insert a catheter, drain
the bladder and then remove the catheter [2]. Single-use
disposable catheters, typically with a hydrophilic coating,
are predominantly used in the UK [3].
There are no accurate prevalence data for CISC use in
the UK. The National Health Service (NHS) England
prescription database recorded 47 million CISC catheter
prescriptions in 2010 at a cost of £64 million [4]. If we
assume each individual uses an average of 25 catheters
per week, this suggests that there are about 36,000 CISC
users in England and perhaps 43,000 in the UK as a
whole. This estimate is in agreement with a primary
care-based estimate which found a prevalence of approxi-
mately 7–8 per 10,000 adults, suggesting an approximate
total of 43,000–49,000 adults in the UK (Fader M.,
personal communication, August 2011).
Recurrent urinary tract infection (UTI) is the common-
est adverse event experienced by CISC users affecting
between 12–88 % of studied cohorts [5]. Differentiation
between asymptomatic bacteriuria, which would not
normally be treated, and symptomatic UTI in these stud-
ies is difficult. One estimate suggests that 50 % of users
have persistent bacteriuria and at least 25 % suffer two or
more symptomatic UTI episodes per year [6]. Conserva-
tively this suggests that up to 10,000 CISC users in the UK
suffer recurrent UTI, the target population for this trial.
Neurological disease, female sex, young age and high
bladder volumes are associated with higher prevalence of
UTI [1]. Escherichia coli (E. coli) is the causative bacter-
ium in 60–70 % of cases [6]. Most episodes are associated
with transient symptoms such as lower abdominal pain,
urethral pain and flu-like symptoms; occasionally systemic
upset can occur with fever and loin pain. Those with
reduced bladder sensation may alternatively complain of
cloudy urine, increased odour and incontinence [7].
Recurrent UTI is distressing and an additional burden for
patients with underlying neurological disease and func-
tional disability [5]. For some there is a risk of renal
damage in the longer term [7] or significant sepsis requir-
ing intensive care and potential mortality.
A number of simple interventions have been trialled to
reduce UTI risk for CISC users, including single-use and
hydrophilic catheters and antiseptics, but none showed
efficacy [2]. A randomised controlled trial (RCT) reported
a benefit of hydrophilic catheters for patients with spinal
cord injury during initial hospitalisation [8]. The need for
strategies to reduce the prevalence of UTI in this popula-
tion has been emphasised by reports in the UK from the
James Lind Alliance and the National Institute for Health
and Care Excellence (NICE) [9, 10].
Once daily low-dose antibiotic prophylaxis is effective
for women without bladder emptying problems who
suffer simple recurrent UTI. Systematic review and
meta-analysis of trials in this patient group showed a
relative risk for UTI (95 % confidence interval, CI)
against placebo of 0.15 (0.08–0.28) [11]. Adverse events
in trials using nitrofurantoin, trimethoprim or cepha-
lexin were mild and rarely associated with withdrawal,
but were more frequent in the antibiotic group with a
relative risk (95 % CI) of 1.78 (1.06–3.0); gastro-
intestinal upset, skin rash and vaginal candidiasis pre-
dominated. Nitrofurantoin appeared more effective than
trimethoprim but resulted in more withdrawals. These
two drugs together with cephalexin are recommended
and licensed for this purpose in the UK [12]. There were
no reports of serious adverse effects such as neuropathy
or pulmonary fibrosis in the nitrofurantoin arms of
randomised studies included in the Cochrane review,
but an observation study of prophylactic nitrofurantoin
noted one episode of possible neuropathy in 219 patients
over 12 months’ use [13].
Current evidence for effectiveness of antibiotic prophy-
laxis by CISC users, the focus for this trial, has been
summarised by a Cochrane review updated to September
2011 [14]. We were unable to identify any further published
or ongoing trials from that date up to December 2015. The
review found six RCTs involving adults (four trials) or
children (three trials) performing CISC for neurological
bladder dysfunction with a total of 406 participants. Five
had placebo as a comparator with either a crossover or
parallel group design, and three each used clinical or
microbiological definition for UTI outcome; the latest
report was 2011. Two of the crossover trials had a duration
of 3 months for each intervention without washout whilst
one had a duration of 5 months for each intervention and a
1-month washout period. The prophylactic agents used
were trimethoprim-sulfamethoxazole (two trials) and nitro-
furantoin (four trials) and a variety of agents (one trial). Par-
ticipant attrition after randomisation ranged from 2–35 %.
One trial using the outcome of clinically defined symptom-
atic UTI found a relative incidence rate (95 % CI) of 0.50
(0.17–1.44) in favour of antibiotic prophylaxis whilst an-
other trial found no difference. For the outcome of micro-
biologically proven symptomatic UTI, one trial found a
relative risk of 0.78 (0.62–0.79) in favour of prophylaxis.
Evidence from four trials showed an overall relative inci-
dence rate (95 % CI) for bacteriuria of 0.61 (0.44–0.87) in
favour of prophylaxis. The review authors concluded that,
although results were promising, there was a lack of
unequivocal evidence for effectiveness of antibiotic prophy-
laxis for CISC users, agreeing with a previous review [15].
Recommendations for future trials were as follows:
Brennand et al. Trials  (2016) 17:276 Page 2 of 18
 Use incidence of symptomatic UTI as the
primary outcome
 Measure antibiotic resistance
 Control for factors increasing UTI risk: sex,
frequency of catheterisation, neurological cause,
frequency of previous UTI, prior use of antibiotic
prophylaxis
None of these trials found any excess harms in the
prophylaxis groups, but ecological changes in patho-
gens were not studied. These results and the need for
further trials have been highlighted in a further narrative
review [16].
In a large RCT of antibiotic prophylaxis of recurrent
UTI in women with normal voiding, it was found that
faecal and urinary carriage of resistant E. coli was
increased from 40 % to 80 % by use of trimethoprim-
sulfamethoxazole once daily prophylaxis but that this
returned to baseline 3 months after discontinuing of the
antibiotic prophylactic therapy [17]. There remains
public health concern regarding the empiric prophylactic
widespread use of antibiotics given the rapid emergence
of resistant strains of bacteria, including E. coli. Anti-
microbial stewardship, including the appropriate use of
antimicrobial prophylaxis, has become a priority.
This background has led us to design a robust pragmatic
trial to determine whether the apparent benefit of antibiotic
prophylaxis seen in small trials amongst specific groups of
CISC users is also seen in a routine care setting and
whether the benefits are worthwhile in terms of harms. The
estimates of prevalence, effectiveness and harms have
allowed us to power the trial conservatively based on what
we consider to be a minimum important difference from
clinician, patient and economic perspectives.
Methods/design
This is a 52-site, pragmatic, patient randomised super-
iority trial designed to answer the question: In people
carrying out CISC who suffer recurrent UTI does an
experimental strategy of once daily antibiotic prophy-
laxis reduce the rate of symptomatic UTI compared to a
control strategy of no prophylaxis? Both groups will
otherwise receive usual care, including on demand
discrete courses of antibiotic treatment for UTI. The
trial will be set in both primary and secondary National
Health Service (NHS) care in the UK. Participants and
their clinicians will not be blinded to the allocated inter-
vention, but central trial staff managing and analysing
trial data will, as far as possible, be unaware of partici-
pant allocation. We will also assess participant percep-
tion of benefit: firstly, by completion of a treatment
satisfaction questionnaire on exit; secondly, by qualita-
tive analysis of semi-structured interviews on trial com-
pletion exploring the views and attitudes of a purposive
sample of participants towards the trial intervention.
The primary economic analysis will assess the cost per
UTI avoided, but we will also perform a cost-utility
analysis and a contingent valuation study. Bacterial
ecological change will be assessed by comparing changes
in resistance patterns of E. coli in participant urine and
perianal swab samples. We have formulated a recruit-
ment plan to progressively build to a target of 372
participants over 28 months. Outcomes will be collected
over 12 months for each participant and analysed at trial
termination according to intention-to-treat principles.
The null hypothesis is that the effectiveness and
cost-effectiveness of a strategy of prophylactic anti-
biotic are not superior to those for no prophylaxis
over 12 months.
The anticipated trial flow for participants is illustrated
in Fig. 1.
Objectives
Primary objectives
The primary objectives are to:
 Determine the relative impact of each intervention
on incidence of UTI over 12 months
 Determine the incremental cost per symptomatic
UTI avoided
Secondary objectives
The secondary objectives are as follows:
 Clinical
○ Determine the relative effect on quality of life
(QoL) amongst trial participants
○ Measure overall satisfaction with prophylactic
antibiotic treatment
○ Assess participants’ perception of benefit at
12 months using qualitative methodology
○ Record adverse effects related to both
prophylaxis and treatment antibiotic use
○ Determine relative rates of hospitalisation
because of UTI
○ Measure difference in renal function by estimated
glomerular filtration rate (eGFR) at 12 months
○ Determine rates of asymptomatic bacteriuria at
12 months
○ Assess ecological change in E. coli isolated from
urine and perianal swabs
 Economic
○ Measure incremental cost per QALY gained
through repeated completion of SF-36
○ Assess participants’ willingness to pay to avoid a
UTI by contingent valuation at end of trial
participation and incorporate these data in the
economic evaluation using a cost-benefit framework.
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Primary outcome measures
The primary outcome is difference in incidence of
symptomatic UTI during the 12-month observation
period. Symptomatic UTI will be defined on fulfil-
ment of two criteria. The first will be the presence
of at least one patient-reported or clinician-recorded
symptom from a predefined list encompassing the
recommendations of the British Infection Association
(BIA) [18], the Centers for Disease Control and
Prevention (CDC) [19] and spinal cord injury UTI
consensus statement [8] comprising: fever (being hot
and sweaty); shivers; cloudy urine; smelly urine;
visible blood in urine; new or increased urinary
leakage (incontinence); lower abdominal pain; having
to catheterise more often; having to rush to catheterise;
pain when one puts the catheter in; feeling generally
unwell (‘fluey’); stiffness or worsening stiffness (spasti-
city) of arms and legs. The second criterion is taking
a discrete treatment course of antibiotics prescribed
by a clinician or as part of a patient-initiated self-
start policy. Occurrence of symptomatic UTI with
prescription of a treatment course of antibiotic will
be captured by:
 Participant log with report alert sent by participant
to trial staff.
Fig. 1 CONSORT diagram showing flow of trial participants through the trial
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 Contact with each participant at least every
3 months by local trial staff and more frequently if
required to aid participant recording of UTI episodes.
 Response to specific enquiry in participant
questionnaire completed at 3, 6, 9 and 12 months.
 End of trial review of hospital and primary care
record at 12 months.
 For any identified treatment course of antibiotics
for UTI the participant will be asked to
complete a multiple choice description of
symptoms that precipitated the request for
antibiotic treatment.
To ensure consistent attribution we will set a hier-
archy of evidence on which to base the primary out-
come. First will be participant-reported episodes of
symptoms that they considered to be due to UTI and for
which they obtained treatment with an appropriate anti-
biotic. If, in discussion with the participant, there is
uncertainty as to whether an antibiotic was taken or if
the stated antibiotic was not of a type normally used for
UTI, the relevant general practitioner (GP) or hospital
record will be checked for confirmation that a prescrip-
tion for an antibiotic to treat UTI was issued (including
previous prescriptions for self-start therapy). Where no
antibiotic prescription was found in the record, we will
ask the participant to confirm the origin of the prescrip-
tion. If we were unable to confirm issuing of either a
single course or self-start supply of antibiotics, then the
primary outcome will not be fulfilled. The second type
of event will be the identification of a prescription of an
antibiotic during the planned 3-monthly interrogation of
healthcare records without a participant report of a UTI.
In this case the participant will be contacted to check
that they did take a treatment course of antibiotics at
that time and to assess their symptom status. If the
participant had no recollection of the antibiotic course,
or if there was no evidence from the participant or
healthcare records of any change to baseline urinary
symptoms, then the episode will be judged not to have
fulfilled the primary outcome.
Primary economic outcome
The primary economic outcome is the incremental cost
per symptomatic UTI avoided. It includes the following
costs associated with the prophylaxis and no prophylaxis
strategies including cost of harms:
○ Treatment costs of drugs and healthcare services
from standard NHS sources such as the British
National Formulary (BNF) and published tariffs from
NHS reference costs
○ Health resource utilisation questionnaire at baseline
and at 6 and 12 months
○ Patient costs from a time and travel questionnaire as
part of the 12 months exit assessment
Secondary outcome measures
Secondary outcome measures will be collected as add-
itional criteria to the primary outcome from inspection of
participant healthcare records, by participant question-
naire or by clinical test performed at specific time points.
The following are also included.
 The rate of UTI will also be alternatively defined as
the incident density rate; the number of UTIs
suffered during the observation period minus days
spent taking treatment courses of antibiotics active
against urinary tract organisms.
 Febrile UTI defined as the primary outcome plus
presence of a recorded fever of more than 38 °C:
○ Confirmed by inspection of primary or
secondary healthcare record by research staff.
 Microbiologically confirmed symptomatic UTI
defined as the primary outcome plus positive
urine culture:1
○ Participants will provide an intermittent
catheter specimen of urine for local analysis as
requested by the treating clinician. This will be
analysed according to clinician decision by the
local microbiology using the local standard
operating procedure (SOP). We will also ask the
participant to send a urine specimen using
provided safe packaging to the central
microbiology trial laboratory in the Newcastle
upon Tyne Hospitals NHS Foundation Trust each
time they consider they have symptoms suggestive
of UTI and intend to commence a course of
antibiotic treatment. This will be analysed and
cultured on receipt and the result used for trial
outcome purposes but not for patient care.
 Antibiotic prescription for asymptomatic UTI
without participant-reported or clinician recorded
evidence of symptom change.
 Asymptomatic bacteriuria defined as a positive urine
culture in the absence of symptoms.
○ Participants will be asked to send a urine sample
to the central laboratory at baseline prior to
randomisation and during asymptomatic periods
in months 3, 6, 9 and 12 of their trial
participation. They will also be separately
consented to provide a urine sample 6 months
after completion of trial (18-month time point).
 Hospitalisation due to UTI defined as an unplanned
visit to hospital for treatment of a UTI which
required at least one overnight stay in hospital.
○ Collected from healthcare record review and
checked from participant report or enquiry.
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 Participant perception of benefit.
○ We will record and analyse semi-structured
interviews with up to 30 participants purposively
sampled from both trial arms on completion of
their 12-month trial period.
 Overall satisfaction with allocated treatment
strategy.
○ Participants will complete the treatment
satisfaction questionnaire for medication at 12
months as part of their completion of trial
questionnaire [20].
 Generic health-related quality of life.
○ Participant completion of the SF-36 1-week
recall questionnaire at baseline, 3, 6, 9 and 12
months and within the first 2 days of each
episode of symptomatic antibiotic-treated
UTI [21].
Adverse effects (harms)
The adverse effects are as follows.
 Adverse effects of antibiotic therapy
○ During antibiotic prophylaxis use
▪ Collected by participation checklist completed
at 3, 6, 9 and 12 months
▪ Recording of relevant data from primary and
secondary care records at 12 months
○ During treatment antibiotic use
▪ Collected as part of participant log during
episode of antibiotic-treated UTI
▪ Recording of relevant data from primary and
secondary care records at 12 months
 Change in renal function defined as estimated
creatinine clearance measured by serum creatinine
blood test at baseline before randomisation and
during an asymptomatic period in month 12
 Change in liver function defined as clinically
significant change in liver function indices measured
by serum liver function tests (LFTs) at baseline and
at 12 months
 Bacterial ecological changes to type and resistance
patterns of E. coli isolated from urine specimens and
perianal swabs analysed at the central laboratory at
baseline prior to randomisation and at 3, 6, 9 and
12 months after randomisation and from
surveillance of other urine specimens submitted to
the central laboratory. Participants will also be
separately consented to provide a urine specimen
and perianal swab together with an antibiotic use
questionnaire 6 months after completion of trial
(18-month time point).
Secondary economic outcomes
The secondary economic outcomes are as follows:
 Incremental cost per QALY gained
○ QALY estimated from responses to repeated
administration of the SF-36 as described above
 Participants’ willingness to pay (WTP) to avoid a UTI
○ Measured by completion of a contingent
valuation questionnaire at end of month 12
Study design and duration
Intervention
This trial is pragmatic in design and, apart from ran-
domisation to prophylaxis/no prophylaxis strategies
and collection of outcome data, participant care will
follow standard pathways in participating UK NHS
sites across both primary and secondary care. Partici-
pants in both trial groups will receive discrete courses
of antibiotics as decided by the responsible clinician
for symptomatic UTI.
Antibiotic prophylaxis (experimental)
The experimental intervention is the use for 12 months
of a once daily low oral dose of an antibiotic active
against common urinary pathogens. The agent to be
used will be selected by the responsible clinician de-
pending on patient characteristics such as previous use,
allergy, possibility of future pregnancy, renal function,
prior urine cultures and local guidance. There is no
universally agreed upon national guidance, but available
evidence suggests use of nitrofurantoin 50 mg (or
100 mg dependent on participant weight), trimethoprim
100 mg or cephalexin 250 mg, in that order of prefer-
ence [23–25]. Renal function will be determined by
estimated glomerular filtration rate (eGFR) at baseline,
and if this is less than 45 mL/min nitrofurantoin will not
be used. Otherwise participants and their clinicians will
be asked to review the prescribing information for each
drug given in the trial documentation to guide selection
of the most appropriate initial agent. At the planned
1-month telephone review, local trial staff will ask
about tolerability of the prescribed medication. If there are
specific and intolerable adverse effects, then switching to
an alternative agent would be advised in consultation with
the relevant clinician with the reasons for the change
recorded. This process would then be repeated at planned
3-monthly reviews and a third agent advised if necessary.
More frequent telephone follow-up will be undertaken
if needed to help the participants become established on
a suitable agent. The aim will be to maintain participants
allocated to the prophylaxis group on prophylaxis for as
long as possible during the 12-month trial period within
tolerance and safety constraints. Participants will be
asked to take the once daily antibiotic prophylaxis as a
single dose at bedtime. If participants in the prophylaxis
group develop symptoms and signs suggestive of break-
through UTI, then they will seek treatment in their usual
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way, predominantly by contacting their GP and starting
a discrete treatment course of antibiotics. In this sce-
nario they will be instructed to stop the prophylactic
antibiotic whilst they are taking a treatment course and
restart it again the day following the last dose they take
of the treatment course. Clinicians and participants will
be advised to use a different agent for treatment than
the one they are taking for prophylaxis. Details of all
treatment antibiotic courses, including the agent used
and the number of days participants actually took the
prescribed antibiotic, will be recorded in the patient log
and trial case report form (CRF). All adverse events will
also be recorded.
No prophylaxis
The control arm will be a strategy of no prophylaxis.
Participants will self-monitor their symptoms as usual
and report to their GP if they develop symptoms and
signs suggestive of UTI requiring treatment.
Standard care for both groups
Apart from the randomised allocation to prophylaxis
and the avoidance of the prophylactic agent as treatment
for symptomatic UTI, there will not be any differences
in the trial protocol concerning care of experimental and
control groups of participants. We will ensure as far as
is possible that participants in both groups receive their
usual care in terms of identification and treatment of
UTI, health surveillance and support related to use of
CISC, and monitoring and treatment of the underlying
cause of their lower urinary tract dysfunction. For
purposes of generalisability of trial results and to input
into relevant trial outcomes and sub-group analysis, we
will record all healthcare episodes for each participant.
We consider standard care for users of clean intermit-
tent self-catheterisation (CISC) who suffer recurrent
UTI to be the use of discrete treatment courses of
antibiotics as indicated by symptoms or signs of UTI.
Treatment will typically involve a 3- or 7-day course
of an antibiotic active against urinary pathogens depend-
ing on severity of symptoms. A urine specimen would
normally be sent for microbiological examination at the
time of starting antibiotic treatment. If therapy was
successful no further action would be required, whereas
if symptoms did not resolve the choice and duration of
antibiotic would be reconsidered in the light of urine
culture result and if necessary a further urine sample
submitted for analysis [18]. Regular renal surveillance
using serum creatinine and ultrasound would also be
expected. Guidance will be provided to participants in
both groups, and their clinicians regarding the use of
urine testing and antibiotic options in terms of agents
used and their duration. Participants in both groups will
continue their regular care with primary and secondary
care clinic visits, access to continence advice and rele-
vant patient support groups according to local practice
and individual preference.
Delivery of interventions
Local clinicians at the site of randomisation will be
responsible for initiating trial medication for those
participants allocated to prophylaxis. If the participant
wishes and if the clinician responsible for their routine
care agrees, then the antibiotic prophylaxis can be con-
tinued beyond the 12-month trial participation period
but without further active monitoring for trial purposes.
Definition of end of study
The end of study is the last participant’s final study
contact at 12 months after his randomisation. We will
separately consent at baseline for the sending of urine
and perianal swab specimens at 6 months after end of
study (18-month time point) together with completion
of an antibiotic usage questionnaire. This is done to
determine the final bacterial ecology outcome.
Sources of bias
To allow randomisation, eligible participants and the
responsible clinician will both need to be sufficiently
uncertain of whether the experimental or control strat-
egy is better for relief of recurrent UTI considering each
individual’s particular circumstances. Given the lack of
high-level evidence as to which is more effective, we will
provide trial information illustrating the uncertainty and
the need for a definitive trial. This will act to ensure that
any selection bias in terms of characteristics of CISC
users willing to be randomised is minimised. An anon-
ymised screening log will be kept at each site listing
demographic and clinical characteristics and reasons for
declining randomisation (if offered) and used for com-
parison of this group with those entering and those
completing the trial. Secondly the characteristics of
participants who cross over at randomisation or at a
later stage, withdraw or regret their allocated treatment
option may differ from those completing 12 months of
their allocated strategy. We will address this by compari-
son of SF-36 scores between these groups measured at
baseline prior to randomisation and following treatment.
Trial literature given to all participants and to their clini-
cians will detail other measures to reduce the risk of UTI
such as adequate fluid intake, increased frequency of cath-
eterisation, cranberry products and, if appropriate for
post-menopausal women, vaginal oestrogen supplements.
Given the lack of blinding, it is possible that partici-
pants allocated to the control of no prophylaxis will be
more likely to seek treatment for symptoms suggestive
of UTI, and that their clinicians may be more likely to
prescribe treatment antibiotic, thus introducing bias to
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our primary outcome. To reduce the potential for this
bias, we will give information on the use of antibiotic
treatment, describing indication and choice of agent, in
trial literature to participants and their GPs according to
established guidance from the British Infection Associ-
ation (BIA) and other groups. We will also include in
the participant information packs advice on when to
seek help regarding symptoms suggestive of UTI and the
use of simple measures to avoid or avert symptomatic
UTI. To ensure uniformity of processing and culture
techniques, we will use the results of analysis performed
at our central laboratory for trial outcomes. The local
result will be used for the study if the central result
is missing.
Target population and sample size
We will recruit from the population of adult users of
CISC. The setting is NHS hospitals and community sites
throughout the UK where CISC use is taught and moni-
tored. We expect to randomise at least 372 participants
over a 28-month period. For primary outcome purposes,
follow-up will continue for 12 months after randomisa-
tion. Participants will be given the option of submitting
an additional urine and perianal swab sample 6 months
after trial completion (18-month time point) to assess
return to baseline of E. coli ecology. Separate consent
will also be asked for permission to access clinical
records for extended follow-up for a further 9 years
(10 years in total) and for life-long linkage to central
NHS databases.
Target population
The target population consists of adult established CISC
users predicted to continue its use for at least 12 months
who have:
1. Suffered at least two episodes of CISC-related
symptomatic oral antibiotic-treated UTI within the
previous 12 months managed in the community or
2. Suffered at least one episode of severe CISC-
related symptomatic parenteral antibiotic-treated
UTI within the previous 12 months requiring
hospital care or
3. Previously received prophylactic antibiotic therapy
for recurrent symptomatic UTI within the
12 months prior to starting prophylactic antibiotic
therapy and who have completed a 3-month
washout period without taking antibiotic prophylaxis
prior to randomisation.
Inclusion criteria
The inclusion criteria are as follows:
 Adult men and women aged ≥18 years
 Completed training of CISC and predicted to
continue use for at least 12 months
 Able to give informed consent for participation
in trial
 Able and willing to adhere to a 12-month
follow-up period
 Have either suffered at least two episodes of
symptomatic UTI related to CISC within the last
12 months, or at least one episode of UTI requiring
hospitalisation, or for those previously prescribed
prophylactic antibiotic for UTI, have completed a
3-month washout period without antibiotic
prophylaxis. Any active symptomatic UTI will be
treated prior to randomisation
 Able to take a once daily oral dose of at least one of
nitrofurantoin, trimethoprim or cephalexin
 Intermittent catheterisation may be performed by
participant, spouse or carer
 No restriction on type of catheter used
Exclusion criteria
The exclusion criteria are as follows:
 Age <18 years
 In learning phase of CISC
 Already taking prophylactic antibiotic against UTI
and declining 3-month washout period without
antibiotic prophylaxis (this will be specifically
monitored in the screening log)
 Inability to take any of the three prophylactic
antibiotic agents due to multiple drug sensitivities
 Women who intend to become pregnant during
planned period of trial participation or who are
pregnant or who are breastfeeding
 Previous participation in this study
 Inability to give informed consent or have primary
outcome information collected
Screening recruitment consent
Participant identification and invitation to participate
We will ask clinical staff at each site to identify eligible
participants through direct contact or by searches of
electronic records. Identified potentially eligible patients
will be sent brief details of the need and purpose of the
study and eligibility criteria. This will emphasise the
pragmatic nature of the study and give a realistic indica-
tion of the burden to participants. Contact details of
central and local trial teams will be provided so that
interested patients can express a willingness to know
more about the project and agree to be contacted by
the research team. Once identified and agreeing to be
contacted by the research team, eligible potential par-
ticipants will be contacted by trial staff and if willing
will be sent or given the trial participant information
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material. This recruitment activity will be coordinated
centrally but administered at each site.
All subjects who agree to participate will be seen by
local research staff in order to go through the con-
sent and randomisation procedure. A screening log
will be kept at each site to document details of
subjects invited to participate in the study. Non-
identifying patient details to allow assessment of
selection bias such as age, number of episodes of UTI
in past 12 months, previous use of antibiotic prophy-
laxis for UTI, type of bladder dysfunction and type of
catheter used will be uploaded to the secure study
website for subsequent analysis. For subjects who
decline participation, the log will document reason
for non-participation. The log will also ensure poten-
tial participants who are ineligible or decline partici-
pation are approached only once. Participants who do
not respond after being sent or given written infor-
mation about the study may be contacted a second
time to ensure they have received the information
and been given the opportunity to participate.
Consent procedures
An informed consent discussion will be undertaken by
site staff authorised in the delegation log. This will
include medical staff and research nurses involved in the
study who will give time for participants to ask any
questions they may have following review of the trial
information pack. Following receipt of information
about the study, participants will be given at least
24 hours and up to as much time as they need to decide
whether or not they would like to participate. Those
wishing to take part will provide written informed
consent by signing and dating the study consent form,
which will be witnessed and dated by a member of the
research team with documented, delegated responsibility
to do so. Written informed consent will always be
obtained prior to randomisation. The original signed
consent form will be retained in the Investigator Site
File, with a copy filed in the clinical notes, a copy given
to the participant and a copy faxed to the central trial
office. Participants will specifically consent to their GP
being informed of their participation in the study. The
right to refuse to participate without giving reasons will
be respected.
Subject withdrawal
Patients will remain in the study unless they withdraw
consent or in the unlikely event that the local Principal
Investigator (PI), Chief Investigator (CI) or trial office
feel it is no longer appropriate for the patient to con-
tinue. If a participant chooses to withdraw, we will seek
continuation of consent for collection of outcome data
from clinical records.
Randomisation
Participant allocation
Randomisation will be administered centrally by the
Newcastle Clinical Trials Unit secure web-based system.
Permuted random blocks of variable length will be used
to allocate participants 1:1 to the control and experi-
mental groups and ensure concealment of allocation
from central trial staff. An individual not otherwise
involved with the study will produce the final random-
isation schedule. Stratification by three variables: (1)
prior frequency of UTI: <4 episodes per year and ≥4
episodes per year, (2) a diagnosis of neurogenic lower
urinary tract dysfunction: yes or no and (3) sex: female
or male, will be performed prior to randomisation to
ensure balanced allocation within these factors. For
those allocated to prophylaxis an appointment will be
arranged, facilitated by trial staff, with the prescribing
clinician to commence prophylaxis. This may be a hos-
pital consultant, a GP or a nurse specialist. Continued
supply will be ensured typically through repeat prescrip-
tion from the individual participant’s GP.
Patients may only be randomised into the study by an
authorised member of staff at the study research site, as
detailed in the delegation log.
Blinding
Assignment to either prophylaxis or no prophylaxis will
not be blinded to either the participant or investigator
or the local research staff (a non-blinded study). How-
ever, central trial staff responsible for data management,
entry and analysis will be unaware of allocated interven-
tion as far as possible.
Data collection and follow-up
Outcome data will be recorded by the participant on
questionnaires, which will be made available in
paper-based and electronic format, and on the work-
sheet by local research staff under a unique identifier
with subsequent electronic entry onto electronic case
report forms (eCRFs) onto the web-based secure
clinical data management system for storage at New-
castle Clinical Trials Unit (CTU). Baseline data will
include demographics, underlying disease character-
istics, details of catheterisation, prior frequency of
UTI and associated usage of healthcare and past
urine microbiological reports, together with symptom
and QoL measures recorded prior to randomisation.
Urine, blood and perianal swab samples will also be
collected at baseline for immediate testing and bank-
ing of serum, urine and E. coli isolates for additional
studies. During the 12 months of study participation,
participants will be asked to keep a simple log re-
cording episodes of suspected UTI from a symptom
and help-seeking point of view. If required, trial staff
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will contact participants approximately monthly to
help complete the UTI logs within a reasonable re-
call window. The patient logs will be validated if ne-
cessary by data from regular inspection of primary
and secondary healthcare records for UTI events and
subsequent direct checking with participants by their
preferred means (telephone, text, e-mail). Other out-
come data will be collected by patient questionnaire
at 3, 6, 9 and 12 months supplemented by regular
inspection of health records. Details of participant
progress will be recorded on CRFs. A schedule of
events is shown in Table 1.
Screening: clinical records and face-to-face
General demographics and eligibility will be checked.
Trial information will be provided to the participant
and consent taken for randomisation, informing GP
of participation in trial, contact by researcher for
semi-structured interview at end of trial participation
(12 months), sending urine and perianal swab speci-
mens to central laboratory 6 months after trial com-
pletion (18 months), access by research team to
clinical records after active trial participation has
ended and storage and use of blood, urine and peri-
anal swab samples for further research.
If the patient is experiencing current symptomatic
UTI, the infection will be treated first and the patient
consented and randomised once symptom free. If the
patient is already on antibiotic prophylaxis for UTI and
agreeable to a 3-month washout period, the patient will
be consented with a plan for randomisation in 3 months
with frequent contact to ensure willingness to participate
is maintained.
Baseline
The following procedures will take place at the
baseline visit, which will be a face-to-face visit, after
consent but prior to randomisation: baseline per-
sonal and health details, completion of SF-36 qu-
estionnaire, creatinine, LFT and creatinine clearance
(via blood test or from clinical records if within
2 months of baseline) with storage of blood sample
for future research, urine and perianal swab spe-
cimens for central microbiological analysis and stor-
age, decision with regard to preferred means of
questionnaire delivery, alerts and best time and
means for contact by trial staff.
Randomisation
Randomisation will be performed as close as possible
to the date of consent (normally immediately after-
wards). Those participants willing to undergo a 3-
month washout period will consent to the study at
the beginning of the washout period, but will not be
randomised or complete the other baseline measures
until the washout period is complete, at which point
their continued consent and eligibility for trial par-
ticipation will be checked.
Post randomisation (discussion of trial documentation:
face-to-face)
The participant log will be completed. Antibiotic
prophylaxis will be discussed and prescribed (if allo-
cated). The discussion will include what to do during
a UTI, how this is defined and how the urine and
perianal swab specimens are delivered to the central
laboratory.
Table 1 Schedule of study interventions and outcome data collection from participant
Intervention/data Visit 1
Initial screen
Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 At time
of UTIConsent, baseline
and randomisation
3 months 6 months 9 months 12 months
Eligibility checklist x
Trial discussed and PIS given x
Informed consent x
UTI questionnaire x x x x x x
Adverse events x x x x x
SF-36 x x x x x x
Resource use questionnaire x x x x
Patient cost questionnaire x
Treatment satisfaction questionnaire x
Contingent valuation questionnaire x
Catheter specimens of urine (CSU) to central laboratory x x x x x x
Perianal swab x x x
Creatinine (eGFR) and LFT x x
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One month (after randomisation and repeated if required:
telephone)
A member of the trial staff will contact the participant
regarding general concerns, understanding of trial docu-
mentation and tolerance of prophylactic antibiotic agent
(if allocated).
Three, six and nine months after randomisation (telephone/
postal or face-to-face - according to individual participant
circumstance)
The participant will complete trial outcome question-
naires and reports of any UTI and associated symptoms
as well as adverse effects. Adherence to prophylaxis will
be checked if allocated to this arm of the trial. During
this time participants will complete the SF-36 and
healthcare resource use questionnaire. They will send in
a urine specimen during an asymptomatic period to the
central laboratory for analysis and storage.
The local research staff will search clinical records
(secondary and primary care) for episodes of UTI,
episodes of UTI which are associated with fever greater
than 38 °C, antibiotic prescription for UTI prophylaxis
and other reasons, episodes of hospitalisation for UTI
and other ill health and results of local laboratory
urine culture.
During episode of symptomatic antibiotic-treated UTI
(telephone/postal or face-to-face - according to individ-
ual participant circumstance)
The participant will complete a trial outcome question-
naire and report on the UTI, associated symptoms,
adverse effects of treatment for UTI and continued ad-
herence to prophylaxis (if allocated). In addition, partici-
pants will complete SF-36 questionnaires and send in a
urine specimen to central and local laboratories prior to
commencing a treatment course of antibiotics.
Local research staff will check clinical records for
documented visits to healthcare for UTI, recorded fever
greater than 38 °C, antibiotic prescription for UTI, hos-
pitalisation and results of local laboratory urine culture.
Twelve months after randomisation (telephone or face-to-
face - according to individual participant circumstance and
local policy)
Participant will complete trial outcome questionnaires
and report on the occurrence of UTIs and associated
symptoms, adverse effects and adherence to prophylaxis
(if allocated). In addition, participants will complete the
SF-36 questionnaire, healthcare resource use question-
naire and patient costs (time and travel) questionnaire,
as well as provide a urine (during asymptomatic period)
and a perianal swab specimen which will be sent to the
central laboratory. Creatinine and LFT (blood test) will
be tested during asymptomatic periods. Finally the
participants will complete a satisfaction with medication
questionnaire and a contingent valuation questionnaire
and will be asked to participate in a semi-structured
interview (if selected and separately consented).
Local research staff will search clinical records (sec-
ondary and primary care) over 12 months of participa-
tion for episodes of UTI, episodes of UTI associated
with fever greater than 38 °C, antibiotic prescriptions for
UTI prophylaxis, UTI or other reasons, episodes of
hospitalisation for UTI or other ill health as well as
results of local laboratory urine culture.
Collection of outcome information by participant ques-
tionnaire may be onerous for some participants because
of co-morbidities and disabilities linked to their under-
lying health condition. Local research staff, local clinical
staff and, where appropriate, the carers of participants will
be asked to help with completion of documentation for
frequent contact with participants as is needed. The
primary outcome will be validated if required from
healthcare records. Full compliance with personal data
protection will be ensured. We will balance provision
of support for participants so that they adhere to their
allocated intervention and record UTI events against
avoidance of distress caused by the trial event schedule.
Urine and perianal swab specimens will be submitted
regularly by participants during the trial to the central
laboratory for selective culture of E. coli. These samples
would not normally be collected during routine care,
and the participants will be asymptomatic for UTI at the
time of specimen collection. We therefore do not plan
to inform the participant or the clinicians responsible
for their care of the results. This policy would be sensi-
tive to clinical concerns and exceptions readily made if,
for example, the participant suffered an episode of se-
vere sepsis and the results of the cultures would be help-
ful to clinical care. Similarly we will not routinely inform
treating clinicians of the result of any positive culture
from CSU sent to the central laboratory during an
episode of symptomatic UTI. The reason for this is the
delayed transit time and hence prolonged period before
any result is available. This in most cases would make
the result unhelpful to clinical care. Participants will be
encouraged to also take a urine specimen to their treating
clinician for local analysis.
Data handling and record keeping
Data will be recorded by site staff authorised by delega-
tion log on electronic case report forms (eCRFs) in the
clinical data management software package (MACRO™).
Data transferred from site to the secure validated data-
base by remote access will be secure and encrypted. Data
will be handled, computerised and stored in accordance
with the UK Data Protection Act 1998. Under the trial
participant consent, identifiable data will be stored in a
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separate and limited access database to allow prepar-
ation and sending of follow-up documentation. The
quality and retention of study data will be the
responsibility of the Newcastle CTU. All study
data will be retained in accordance with the latest
directive on Good Clinical Practice (GCP) and local
policy.
Clinical data will be entered into the database re-
motely at each site by the local investigator or
another member of the site research team with dele-
gated responsibility for this activity, together with
data from questionnaires completed at face-to-face
visits with participants. Questionnaires returned by
post to the trial management office will be entered
there. Trial management staff and database manage-
ment staff will work closely with local site research
teams to ensure that the data are as complete and
accurate as possible. The Newcastle CTU will be
responsible for checking and requesting missing data.
Two reminders will be sent to participants for
prompt return of the questionnaires. Extensive range
and consistency checks will further enhance the
quality of the data. Data collected during the course
of the research will be kept strictly confidential and
accessed only by members of the trial team. Patients
will be allocated an individual specific trial number
to allow anonymised versions of the secure database
to be available to the trial team and subsequently
more widely under open data access arrangements.
The management system will be used to ensure trial
correspondence is sent to each participant using
their preferred mode of delivery. To comply with the
fifth principle of the Data Protection Act 1998,
personal data will not be kept for longer than is
required for the purpose for which it has been
acquired. The sponsor is responsible for ensuring
that trial data are archived appropriately. Essential
data will be retained for a period of at least 10 years
following close of study in line with sponsor policy
and the latest directive on GCP (2005/28/EC). Cal-
dicott approval for use, transfer and storage of
participant identifiable information will be obtained
at each site.
Data sharing
Data will be archived in accordance with the Newcastle
CTU standard operating procedure (SOP) and European
Commission Directive 2005/28/EC Article 17 and made
permanently available to the wider research community
through deposition at the UK Data Archive. Research
participants’ confidentiality will be protected through the
removal of personal, confidential and sensitive data. In
addition to data files (rendered as CSV-delimited text),
data list files will provide descriptions of all variables,
including how each variable was constructed and calcu-
lated where appropriate.
Discontinuation rules
The trial may be prematurely discontinued on the basis
of new safety information or for other reasons given by
the Data Monitoring Committee (DMC) and/or Trial
Steering Committee (TSC), sponsor, regulatory authority
or ethics committee concerned. The TSC will give advice
on whether to continue or discontinue the study and
make a recommendation to the funder and sponsor. If
the study is prematurely discontinued, active participants
will be informed and no further participant data will
be collected.
Study adherence and withdrawal
Assessment of adherence
Outcome data will be collected remotely whenever
feasible by participant completion of postal or secure
web-based questionnaires. This will be supplemented by
e-mail or text alerts to participants notifying the need to
complete questionnaires with additionally up to two
reminders in these formats for non-responders. Local
research staff will make use of planned routine clinical
visits, whether for the underlying health condition or
urinary tract monitoring, to check completion of trial
documentation and collect clinical outcome information
such as urine and perianal swab specimens. Participants
allocated to prophylaxis will be contacted after 1 month
to assess tolerability and if necessary allow change to
alternative agent with re-checking of tolerability after a
further month. We will assess adherence to the allocated
arm (prophylaxis or no prophylaxis) by 3-monthly con-
tact with the participant to check tolerability and
surveillance of their primary healthcare record to record
issuing of relevant prescriptions and consultations in-
volving discussion of UTI treatment. We will contact
participants more frequently if they need assistance to
complete trial documents, particularly the UTI log.
All information will be recorded in the relevant CRF.
If we do detect change from allocation, we will explore
and record the reasons for this with the participant and
the relevant clinician. Wherever possible these partici-
pants will remain on study and continue collection of
planned outcome information. Trial literature will em-
phasise the need to adhere to the allocated strategy
during the 12-month trial period if possible and will
record any deviation. Multiple switching between prophy-
lactic agents will be allowed. Previous studies suggest that
this will affect approximately 12 % of participants [26],
although a higher rate was seen in children (48 %) [27].
The trial statistician will monitor attrition rate against
our anticipated maximum of 15 % and report to the
TSC and DMC.
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Withdrawal of participants
Participants have the right to withdraw from the study
at any time for any reason, and without giving a reason.
The investigator will also withdraw patients from the
study intervention if it is judged to be in the patient’s
best interests. It is understood by all concerned that an
excessive rate of withdrawals can render the study
uninterpretable; therefore, unnecessary withdrawal of
patients should be avoided. Should a patient decide to
withdraw from the study, all efforts will be made to
report the reason for withdrawal as thoroughly as
possible.
There are three withdrawal options:
1. Withdrawing completely (i.e. withdrawal from
allocated treatment and consent to follow-up
data collection)
2. Withdrawing from active participation in the trial
but allowing continued review by the research team
of healthcare records
3. Investigator-led participant change in status would
be considered for the following reasons: Prophylaxis
arm: Unable to tolerate any suitable antibiotic agent
or pregnancy.
No prophylaxis arm: Change in circumstance
whereby starting prophylaxis is an urgent clinical
necessity within 6 months of randomisation or
pregnancy.
We will encourage participants who decide to with-
draw to choose option 2, but if they wish to withdraw
completely we will retain data collected up to the point
of withdrawal. Participants will be asked if they would
be happy for the reason for the decision to withdraw to
be recorded. Participants who withdraw completely will
not be replaced, but the rate of withdrawal will be
monitored and reported to the DMC.
Statistical analysis
An analysis of the primary outcome measure (incidence
of UTI) for the full study will be performed both for the
full data set and for the separate sub-groups defined by
high and low baseline UTI rate (as specified during
stratification for the randomisation process) using both
the Poisson rate test and an incidence density ratio ap-
proach to allow for the different treatment durations;
regression or generalised linear modelling approaches
will be used to adjust for the effects of covariates. The
model selection process will include the stratification
factors (prior rate of UTI, presence of neurological dis-
ease and gender) and other baseline variables (person
doing CISC [self or other], asymptomatic bacteriuria,
age, type of catheter, use of antibiotic prophylaxis for
UTI in the previous 12 months prior to randomisation
and presence of bladder augmentation). The inclusion of
interaction terms such as site will also be explored. The
inclusion of baseline values as covariates will additionally
enable the examination of possible interactions between
effects observed and these values. Not all covariates
mentioned above will be included in the final model, but
all will be considered during the model selection process.
A number of additional secondary analyses will also be
undertaken to examine the secondary outcome variables.
Febrile and microbiologically confirmed UTI, asymp-
tomatic bacteriuria and hospitalisation due to UTI will
be analysed in a manner analogous to that for the
primary outcome. Analyses of other outcomes will use
similar regression or analysis of variance/covariance-
based approaches as described above to compare be-
tween treatment groups while allowing for the effects of
covariates. Baseline measures would be included in the
analysis, either considered as possible covariates or by
exploring changes in outcome measures from baseline.
Analysis will be carried out primarily on an intention-to-
treat basis, although other exploratory analyses such as
per-protocol may also be considered. Data will be
analysed at the end of the study; there are no planned
interim analyses. Safety data will be regularly and
frequently reviewed but will not be subjected to statis-
tical analysis. Data with missing observations due to loss
to follow-up will be examined to determine both the
extent of the missing data and whether they are missing
at random or are informative. If data are missing to a
sufficient extent, the use of appropriate multiple imput-
ation techniques will be considered.
Economic analysis
Analyses will be carried out from the perspective of the
UK NHS and personal and social services, but we will
also take a wider perspective by including costs borne by
the participants and their families. All unit costs will be
derived using routine data sources [28] and study-
specific estimates. Where appropriate, discounting will
be applied to costs and outcomes at UK recommended
rates [29]. Data on use of services will be combined with
appropriate unit costs to produce a cost for each trial
participant. From these a mean cost per intervention
and a mean cost taking into account patient and carer
costs will be estimated. Results for cost-effectiveness will
be presented as point estimates of mean incremental
costs and effects. The within-trial analysis will also com-
pare changes in health-related quality of life (HRQoL)
based on responses to the SF-36 and converted into the
SF-6D [30] to estimate quality-adjusted life years
(QALYs) using the area under the curve approach. They
will subsequently be used in a cost-utility analysis based
on avoidance of UTI. The results will be presented as
point estimates of mean incremental costs and QALYs.
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Both cost-effectiveness and cost-utility analyses will
include deterministic and stochastic sensitivity analyses,
presented as point estimates and cost-effectiveness ac-
ceptability curves.
A contingent valuation study at 12 months will collect
individuals’ willingness to pay for a reduction in the
number of UTIs. For a given level of income, higher
monetary values indicate that they would derive greater
benefit. This method will enable us to place a monetary
value on the health outcome, going beyond the QALY
framework, and also to conduct a cost-benefit analysis.
The cost-benefit analysis expresses both costs and bene-
fits in commensurate units, which enables a comparison
to be made between strategies [31]. The decision rule for
the cost-benefit analysis is therefore relatively simple: if
the benefits measured in pounds sterling (£) exceed the
costs, this represents a gain in welfare and the strategy is
deemed worthwhile [32]. Results will be presented as in-
cremental net benefits (net benefits = mean willingness
to pay – mean cost of intervention). Both stochastic and
deterministic sensitivity analyses will be conducted and
the results presented as incremental net benefit curves
and as the probability that each treatment would be con-
sidered cost-effective.
Sample size calculation
We plan to recruit 372 participants to the trial. Based on
systematic reviews [11, 14] and expert (including patient)
opinion, we believe that an overall 20 % reduction in
symptomatic UTI rate from an average of 3 to 2.4
episodes per year represents the minimum clinically
important difference. Using the Poisson rate test, comple-
tion of the study by 158 participants in each arm, 316 in
total, would give 90 % power to detect this difference at
the 5 % level. A total of 372 would allow for a 15 %
attrition rate estimated from previous trials included in
the systematic review. The attrition rate will be monitored
and the sample size increased if necessary. Half this
sample size would give 92 % power to detect a 25 % differ-
ence in the high frequency sub-group (from 4 to 3
episodes per year) and more than 99 % power for a 50 %
reduction in the low frequency group (from 2 to 1) with-
out allowance for multiple testing. We will approach
approximately 750 eligible patients, anticipating a 50 % re-
cruitment rate. We are currently recruiting from 52 sites
which are coordinated through seven trial hubs. This
number will be adjusted according to site and overall
recruitment rate. For the qualitative sub-study of partici-
pant perception of benefit we will interview 30 trial par-
ticipants who, at the time of trial consent, expressed a
willingness to be interviewed at completion. We will create
a purposive sample of approximately 20 participants from
the prophylaxis arm and 10 from the no prophylaxis arm
including some with neurological disease and some who
did not complete the trial as allocated. We anticipate this
will be sufficient to saturate themes arising from qualitative
analysis of interview transcripts. For contingent valuation
we will use a sample of 100 participants in each group; 200
in total will complete an exit questionnaire.
Qualitative analysis of participant exit interviews
We will use qualitative methodology to conduct and
analyse semi-structured interviews with a purposive
sample of trial participants to explore their views and
experiences of self-catheterisation, the impact of UTI on
their well-being, attitudes towards use of antibiotic
prophylaxis and adherence to this treatment. This will
inform interpretation of measures of effectiveness, par-
ticularly regarding adherence, and will also add insights
that can further refine implementation of the interven-
tion into practice. The sample will be weighted towards
the prophylaxis arm in order to better explore the
comparative experiences of this intervention for people
with neurological and non-neurological underlying con-
ditions. Interviews lasting approximately 45 minutes will
be conducted by telephone with development of the
schedule conducted in an iterative fashion in order to
follow up unanticipated themes. Constant comparison
techniques to check experiences against those of others
in the sample will be used to ensure that the analysis
represents all perspectives.
Interviews will be recorded, transcribed verbatim,
anonymised and stored electronically with restricted
access. Data will be transcribed and uploaded into filing
software and coded for recurrent themes drawing on a
framework analysis approach [33]. Transcripts will be
charted, classified and organised according to key themes,
concepts and emergent categories. The analytic matrix
will include key attributes such as antibiotic use, sex,
degree of adherence and neurological/non-neurological
condition and will facilitate cross-referencing attributes
with nodes/themes. Transcripts will be read by more than
one researcher and discussed with the wider team to
establish a rigorous analytical framework to find true
patterns in the data. This will go beyond description to
evaluate meanings of participants’ experiences in greater
depth. Negative cases will be sought and further interrogated
to explore the reasons for variation of experience or views
and unanticipated themes will be searched for [34, 35]. A
sample (n = 5) of coded transcripts will be checked and
verified by a second researcher to ensure reliability.
Study monitoring
Quality control will be maintained through adherence to
SOPs published by the Newcastle CTU, study protocol,
the principles of GCP, research governance and clinical
trials for investigational medicinal products regulations.
An independent Data Monitoring and Ethics Committee
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(DMC) has been convened to undertake independent
review. The purpose of this committee will be to moni-
tor efficacy and safety endpoints, and it will operate
according to written terms of reference linked to the
DAMOCLES charter [35]. Only the DMC will have
access to full unblinded study data, if requested, prior to
completion of the trial. All analyses will follow a care-
fully documented statistical analysis plan. The TSC and
DMC will be asked to review and comment on this plan
prior to analysis. A single main analysis will be
performed at the end of the trial when all follow-up has
been completed. The DMC will meet initially to agree
on terms of reference and other procedures. The final
trial report will contain full details of the analytical
methodology. The DMC will meet at least three times:
at the start, middle and completion of the study. At the
first meeting, the committee will agree on its charter of
operation and discuss and advise on criteria for the need
for interim analysis and adoption of a formal set of
stopping rules for efficacy or safety.
A Trial Steering Committee (TSC) has been established
to provide overall supervision of the trial. The committee
will meet approximately every 6 months during recruit-
ment and annually thereafter for the duration of the trial.
Monitoring of study conduct and collected data will be
performed by a combination of central review and focused
site monitoring visits to ensure the study is conducted in
accordance with GCP. Study site monitoring will be
undertaken by the central trial management team. The
main areas of focus will include validity of consent, serious
adverse events and essential documents in study. Site
monitoring will include review of all original consent
forms as part of the study file. Confirmation of the pres-
ence of a copy in the patient hospital notes may be
requested for 10 % of participants, and comparison of all
original consent forms against the study participant identi-
fication list, verification of all reported serious adverse
events against clinical records (source data verification),
the presence of essential documents in the Investigator
Site File and study files and verification of primary
endpoint data and eligibility data for 10 % of participants
entered in the study may be requested. Central monitoring
will include review of applications for study authorisations
and submissions of progress/safety reports for accuracy
and completeness prior to submission, review of all docu-
mentation essential for study initiation prior to site
authorisation and statistical monitoring for outlier sites
and unusual data patterns.
All monitoring findings will be reported and followed
up with the appropriate personnel in a timely manner.
The study may be subject to inspection and audit by the
Research and Development Directorate, Newcastle upon
Tyne Hospitals NHS Foundation Trust, under their
remit as sponsor, and by other regulatory bodies to
ensure adherence to GCP. The site investigators and
their institutions will permit trial-related monitoring,
audits, REC review and regulatory inspection, providing
direct access to source data/documents.
Ethical approval and confidentiality
The conduct of this study will be in accordance with the
recommendations for physicians involved in research on
human subjects adopted by the 18th World Medical As-
sembly, Helsinki 1964 and later revisions. Favourable
ethics opinion covering recruitment across all UK NHS
sites was obtained from National Research Ethics Service
Committee North East - Sunderland on 1 August 2014
(reference: 13/NE/0196). Local approvals were obtained
from the Newcastle upon Tyne Hospitals NHS Founda-
tion Trust, Northumberland Tyne and Wear NHS Foun-
dation Trust, Newcastle Primary Care Trust, City Hospital
Sunderland NHS Foundation Trust, Mid Yorkshire Hospi-
tals NHS Trust, Leeds Community Healthcare NHS Trust,
North Bristol NHS Trust, Bristol Primary Care Trust, Bath
and North East Somerset Primary Care Trust, Weston
Area Health NHS Trust, Cambridge University Hospitals
NHS Foundation Trust, Southampton University Hospital
NHS Trust, NHS Greater Glasgow and Clyde, SPCRN
North, County Durham Primary Care Trust, Dorset
Primary Care Trust, Hampshire Primary Care Trust,
Solent NHS Trust, Leeds Teaching Hospitals NHS Trust,
Leeds Community Healthcare NHS Trust, Ipswich Hos-
pital NHS Trust, Southport and Ormskirk Hospital NHS
Trust, University Hospital Birmingham NHS Foundation
Trust, Gloucestershire Hospital NHS Foundation Trust,
Gloucestershire Primary Care Trust, South Tees Hos-
pitals NHS Foundation Trust, Royal Bolton Hospital
NHS Foundation Trust, NHS Tayside, Royal National
Orthopaedic Hospital NHS Trust, Guy's and St Thomas’
NHS Foundation Trust, NHS Lothian, University Ho-
spitals Coventry and Warwickshire NHS Trust, NHS
Ayrshire & Arran, Sheffield Teaching Hospitals NHS
Foundation Trust, East Kent Hospitals University NHS
Foundation Trust, The Royal Wolverhampton Hospitals
NHS Trust, Imperial College Healthcare NHS Trust,
Bedford Hospital NHS Trust, Salford Royal NHS Founda-
tion Trust, NHS Highland, Northern Devon Healthcare
NHS Trust and North Lancashire Teaching Primary Care
Trust R&D committees.
Informed consent
All participants will undergo a process of informed consent
which will include the delivery of balanced written informa-
tion concerning the need and overall benefit of the trial
followed up by discussion with a local trial coordinator.
This discussion will include a check of understanding
concerning benefits and risks of participation and ensuring
that participants accept that the treatment will be allocated
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at random regardless of any personal preference they
may have. Participants will be free to withdraw their
consent at any time, and if this happens they will be
given the opportunity to withdraw their data collected
up to that time.
Compliance with Medicines for Human Use (Clinical Trials)
Regulations
We have made a risk assessment of the potential
hazards associated with this trial including those
occurring and resulting in harm to the participants or
researchers. The investigational medicinal products
(IMPs) to be used in the trial are all licensed in
dosage and form for use in prophylaxis against UTI
in the UK and are standard care for this indication
[23–25]. We thus judge that from an IMP perspective
there is low risk to trial participants. Apart from the
intervention in the experimental arm, participants in
both arms of the trial will be subject to routine
clinical care only, and we therefore consider that risks
other than those related to the IMP are also low.
Risks associated with the design and methods of the
trial including the clinical procedures specified in the
protocol, participants’ rights related to consent and
protection of data and the reliability of trial results
have also been assessed. The robust design of the
study to mitigate and manage these risks has led to
the decision, supported by the sponsor, to be granted
‘Type A’ status (low risk - notification only) from the
UK Medicines and Healthcare Products Regulatory
Agency (MHRA), allowing for a risk-proportionate trial
management and monitoring approach to the trial. A
structured safety monitoring plan will be made to assess
risk management by all relevant parties including the
sponsor, regulators, pharmacists and regulatory and
governance staff. This was submitted to the MHRA along
with the notification application.
Confidentiality
Personal data will be regarded as strictly confidential.
The study will comply with the Data Protection Act,
1998. All study records and Investigator Site Files will be
kept at site in a locked filing cabinet with restricted
access. All trial laboratory samples will be labelled with a
unique study identification number and patient date of
birth only (linked in anonymised form).
SPIRIT
This protocol has been written in accordance with
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) guidelines. Please refer
to the SPIRIT checklist that was submitted alongside
this publication for further details (see Additional
file 1).
Discussion
This study is a pragmatic patient-oriented trial aim-
ing to capture a true representation of the actual
patient population. For this reason it was decided to
not discriminate against specific catheter types. In
addition, inclusion/exclusion criteria were chosen to
allow the capturing of the relevant patient group.
The importance of this is also reflected in the mixed
recruitment from both primary and secondary care
sites, which will aid in achieving a balanced patient
population.
This trial seeks to follow standard local patterns and
pathways of care with the only additional intervention
being randomisation between the two strategies under
test and collection of baseline and outcome information.
Given the degree of uncertainty regarding the use of
antibiotic prophylaxis against UTI in this patient group,
there is as yet no definitive evidence that randomisation
to either arm will result in greater benefit or harm for
participants; this being the reason for the trial.
The use of antibiotic prophylaxis may be associated
with adverse effects related to individual agents or
changes to normal bacterial flora. These risks will be
minimised by carefully worded trial information given to
participants randomised to prophylaxis and their clini-
cians to enable selection of the individually most ap-
propriate agent and information concerning use of oral
probiotics. The order of preference of prophylactic agents
we will advise, together with guidance to avoid the use of
other agents, will ensure that the great majority of partici-
pants will be able to use one of the three recommended
agents and switch between them if necessary. We have
planned what we believe is a sufficiently comprehensive
but feasible program of bacterial surveillance that will
detect potentially serious changes to bacterial ecology
in the trial groups. The main benefit will be to re-
solve uncertainty concerning the effectiveness of anti-
biotic prophylaxis in this group, thereby reducing
variation in practice.
Funder statement
This article/paper/report presents independent re-
search funded by the National Institute for Health
Research (NIHR). The views expressed are those of
the author(s) and not necessarily those of the NHS,
the NIHR or the UK Government’s Department of
Health.
Trial status
The AnTIC study is currently recruiting in 52 UK
research centres. The first patient was randomised on
26 November 2013, and recruitment is anticipated to
end in January 2016 with follow-up completed in
February 2017.
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Endnotes
1The definition chosen was the laboratory report of one
or two isolates of a uropathogen at ≥105 cfu/mL or a sin-
gle isolate at ≥104 cfu/mL in a symptomatic participant
[22]. The central laboratory result will be used preferen-
tially for this outcome with the local result used only if a
suitable sample was not received by the central laboratory.
Additional file
Additional file 1: AnTIC protocol trials publication SPIRITchecklist.
(DOC 119 kb)
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